Residency · Residency · Preventive Medicine

Cancer Prevention Beyond Screening: Lifestyle and Chemoprevention

Overview

Cancer is the second leading cause of death in the U.S. (~600,000 deaths/year) and first in adults under 85. An estimated 40-50% of cancers are attributable to modifiable risk factors. Primary prevention (reducing incidence) is distinct from secondary prevention (screening/early detection) Key modifiable risk factors: tobacco, obesity, physical inactivity, diet, alcohol, ultraviolet radiation, infections (HPV, HBV, H. pylori) Chemoprevention refers to pharmacologic agents taken to reduce cancer risk in high-risk individuals. The preventive medicine physician integrates population-level risk reduction with clinical chemoprevention counseling.

Lifestyle Factors in Cancer Prevention

Tobacco

Responsible for ~30% of all cancer deaths. Causally linked to cancers of the lung, head/neck, esophagus, stomach, pancreas, kidney, bladder, cervix, colon, and acute myeloid leukemia. Cessation at any age reduces cancer risk; 10 years after quitting, lung cancer risk drops by ~50%. Secondhand smoke exposure causes ~7,000 lung cancer deaths/year in U.S. non-smokers.

Obesity and Body Fatness

IARC classifies excess body fatness as a cause of >=13 cancers: breast (postmenopausal), colorectal, endometrial, esophageal adenocarcinoma, kidney, liver, gallbladder, pancreas, stomach cardia, ovarian, thyroid, meningioma, multiple myeloma. Mechanisms: chronic inflammation, insulin/IGF-1 signaling, sex hormone dysregulation, adipokine effects. Population-attributable fraction: obesity accounts for ~8% of all cancers in the U.S. Weight loss (particularly sustained >=5%) reduces cancer risk -- bariatric surgery studies show 33% reduction in cancer incidence.

Physical Activity

Regular physical activity reduces risk of colon cancer (~20-25%), breast cancer (~20-25%), endometrial cancer (~20%), and possibly lung, liver, and stomach cancers. Mechanisms: reduced insulin/IGF-1, anti-inflammatory effects, improved immune function, reduced sex hormones. Dose-response: greater activity = greater risk reduction; benefit seen at recommended levels (150 min/week moderate-intensity) Sedentary behavior independently associated with increased cancer risk.

Diet

Processed meat (IARC Group 1 carcinogen): ~18% increased colorectal cancer risk per 50 g/day. Red meat (IARC Group 2A): probable colorectal carcinogen; ~17% increase per 100 g/day. Fiber: inverse association with colorectal cancer (~10% risk reduction per 10 g/day) Fruits and vegetables: modest inverse association with aerodigestive cancers; overall cancer prevention benefit is weaker than previously thought. Whole grains: associated with reduced colorectal cancer risk. Ultra-processed foods: emerging association with overall and specific cancer risks. Dietary patterns: Mediterranean and DASH-type diets associated with lower overall cancer incidence.

Alcohol

IARC Group 1 carcinogen; causally linked to cancers of the oral cavity, pharynx, larynx, esophagus, liver, colorectal, and breast. No safe threshold for cancer: even light drinking (1 drink/day) increases breast cancer risk by ~7-10%. Dose-response relationship: risk increases linearly with consumption. Combined alcohol and tobacco use: multiplicative (not merely additive) risk for head/neck and esophageal cancers. Population-attributable fraction: alcohol causes ~5.5% of cancers and 5.8% of cancer deaths worldwide.

Ultraviolet Radiation

Primary cause of skin cancers (melanoma, basal cell carcinoma, squamous cell carcinoma) Indoor tanning: IARC Group 1 carcinogen; 59% increased melanoma risk with any indoor tanning before age 35. Prevention: sun-protective behaviors, sunscreen (SPF >=30, broad-spectrum), avoidance of tanning beds. USPSTF: counseling for fair-skinned individuals aged 6 months-24 years to minimize UV exposure (B recommendation)

Infection-Related Cancer Prevention

HPV Vaccination

HPV causes ~36,000 cancers/year in the U.S.: cervical, oropharyngeal, anal, vulvar, vaginal, penile. 9-valent HPV vaccine (Gardasil 9): prevents ~90% of HPV-related cancers. ACIP recommendation: routine vaccination at ages 11-12; catch-up through age 26; shared clinical decision for ages 27-45. Australia on track for cervical cancer elimination through high-coverage vaccination + screening programs. Impact: 88% reduction in HPV infections in vaccinated age groups in the U.S.

Hepatitis B Vaccination

Chronic HBV causes hepatocellular carcinoma. Universal infant HBV vaccination (since 1991 in U.S.) has reduced chronic HBV and liver cancer in vaccinated cohorts. ACIP expanded recommendation: universal HBV vaccination for all adults through age 59 (2022)

H. pylori Eradication

Chronic H. pylori infection causes gastric adenocarcinoma and MALT lymphoma. Eradication reduces gastric cancer risk by ~35-50% in high-risk populations. Mass screening and treatment in high-prevalence populations (East Asia) under investigation. Not currently recommended for routine screening in low-risk U.S. populations.

Chemoprevention

Aspirin for Colorectal Cancer

Aspirin reduces colorectal cancer incidence and mortality -- strongest evidence for >=10 years of regular use. USPSTF (2022): insufficient evidence to recommend aspirin for CRC prevention specifically; cardiovascular benefit/risk assessment should drive decision. Previous 2016 recommendation: low-dose aspirin for adults 50-59 with >=10% 10-year CVD risk (included CRC benefit as co-benefit) -- subsequently withdrawn. ACS: does not recommend aspirin solely for cancer prevention. Mechanism: COX-2 inhibition, anti-inflammatory effects, platelet inhibition.

Tamoxifen and Raloxifene for Breast Cancer

USPSTF (B recommendation): offer risk-reducing medications to women at increased breast cancer risk (>=3% 5-year risk or known BRCA mutation) Tamoxifen: reduces invasive breast cancer by ~49% over 5 years (NSABP P-1 trial); can be used pre- or postmenopausal. Raloxifene: reduces invasive breast cancer by ~38% (STAR trial); postmenopausal only; fewer side effects than tamoxifen. Aromatase inhibitors (exemestane, anastrozole): ~53-65% reduction in breast cancer; postmenopausal women; bone loss and arthralgia. Uptake is very low despite proven efficacy -- <5% of eligible women use chemoprevention. Barriers: fear of side effects (VTE, endometrial cancer with tamoxifen), low awareness, insufficient counseling.

Finasteride/Dutasteride for Prostate Cancer

PCPT trial: finasteride reduced prostate cancer incidence by 25% but initially raised concern for higher-grade tumors (detection bias likely) REDUCE trial: dutasteride reduced prostate cancer by 23%. Not widely adopted; no USPSTF or ACS recommendation for chemoprevention.

<image>A pie chart or stacked bar showing the attributable fraction of cancer deaths by modifiable risk factor in the U.S.: tobacco (30%), obesity (8%), alcohol (5.5%), physical inactivity (5%), diet (5%), UV radiation (5%), infections (HPV, HBV, H. pylori, ~4%), and other environmental/occupational exposures. The chart emphasizes that collectively, modifiable factors account for roughly 40-50% of cancer incidence. Cancer prevention education illustration.</image>

<image>A comparison table formatted as an infographic showing breast cancer chemoprevention options: tamoxifen (49% risk reduction, pre/postmenopausal, side effects: VTE/endometrial cancer), raloxifene (38% reduction, postmenopausal only, fewer side effects), exemestane (53% reduction, postmenopausal, bone loss/arthralgia), and anastrozole (53% reduction, postmenopausal, bone loss/arthralgia). Eligibility criteria (>=3% 5-year risk by Gail model or BRCA mutation) are noted. Breast cancer chemoprevention education illustration.</image>

<image>A timeline showing the impact of HPV vaccination on HPV-related cancer prevention globally. Milestones include: 2006 FDA approval of quadrivalent HPV vaccine, 2014 9-valent vaccine approval, and projected cervical cancer elimination in high-coverage countries (Australia by ~2035). A graph overlay shows the decline in HPV-type 16/18 prevalence among vaccinated cohorts and the projected reduction in cervical cancer incidence over decades. HPV vaccination and cancer prevention education illustration.</image>

Clinical Pearls

Even light alcohol consumption (1 drink/day) increases breast cancer risk -- there is no safe level of alcohol for cancer prevention; this contradicts older messaging about "moderate" drinking benefits. HPV vaccination is the most effective cancer prevention vaccine -- universal vaccination at ages 11-12 could prevent ~90% of HPV-related cancers, including oropharyngeal cancers in males. Breast cancer chemoprevention is dramatically underutilized (<5% of eligible women) despite USPSTF B-grade recommendation -- proactive risk assessment and counseling are essential. For boards: know the IARC Group 1 carcinogens (tobacco, alcohol, processed meat, UV, HPV), the breast cancer chemoprevention agents and their risk reductions, and the current status of aspirin for CRC prevention. Obesity is now recognized as a cause of at least 13 cancers -- weight management counseling should frame cancer risk alongside metabolic and cardiovascular risk.

References

• Islami F, et al. Proportion and number of cancer cases attributable to potentially modifiable risk factors in the U.S. CA Cancer J Clin. 2018;68(1):31-54.
• Fisher B, et al. Tamoxifen for prevention of breast cancer: NSABP P-1 study. J Natl Cancer Inst. 1998;90(18):1371-1388.
• USPSTF. Medications to reduce risk of breast cancer. JAMA. 2019;322(9):857-867.
• Lauby-Secretan B, et al. Body fatness and cancer -- viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-798.
• Lei J, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340-1348.

How to think about this

Cancer prevention extends far beyond screening tests, encompassing a broad range of lifestyle modifications and targeted pharmacological interventions. For many common cancers, the most impactful prevention strategies lie in addressing modifiable risk factors like tobacco use, obesity, physical inactivity, diet, and alcohol consumption. These factors contribute to a substantial proportion of cancer diagnoses. Additionally, vaccination against oncogenic infections such as human papillomavirus (HPV) and hepatitis B virus (HBV) offers highly effective primary prevention. Chemoprevention, using medications like tamoxifen or aspirin in specific high-risk populations, represents another layer of targeted risk reduction. The challenge and opportunity in preventive medicine is to integrate these diverse approaches, moving beyond simply treating disease to actively preventing its onset through both population-level health promotion and individualized clinical counseling.

Check yourself with 2 bullets

• What are the major modifiable risk factors contributing to the highest proportion of cancer cases in the U.S.?
• For which cancers is there strong evidence supporting chemoprevention, and what are common barriers to its utilization?

Read this lecture as Markdown